Study Highlights Blood tests showed that 100% of patients in the artificial intelligence intervention arm received full therapeutic benefit, compared to only 50% in the control arm. This was the first randomized controlled trial to compare adherence rates of all 3 DOACs (dabigatran, rivaroxaban, and apixaban) and warfarin together based… Read More
This is my archive
AiCure wins Best Technological Development in Clinical Trials Award – Patient-focused at The 12th Annual Scrip Awards.
The Scrip Awards acknowledge and commend the pharmaceutical sector’s stand-out performers across all areas of the industry, recognising both corporate and individual achievements. AiCure’s artificial intelligence DOT smartphone app won the award for Best Technological Development in Clinical Trials Award – Patient-focused at the 12th… Read More
AICURE IS AWARDED TWENTIETH PATENT FOR ARTIFICIAL INTELLIGENCE PLATFORM US patent 9,486,720, titled “Method and Apparatus for Monitoring Medication Adherence” New York, Nov. 8, 2016 — AiCure, a clinically-validated artificial intelligence company that visually confirms medication ingestion on smartphones, has been awarded its twentieth patent. The patent enables AiCure’s proprietary visual… Read More
Data Presented Today at Connected Health Symposium Highlight Suboptimal and Undetected Nonadherence in Patients Diagnosed with Ischemic Stroke New York, Oct. 27, 2016 — AiCure, a clinically-validated artificial intelligence company that visually confirms medication ingestion on smartphones, announced that study results presented today during the Connected Health Symposium validate that use of the AiCure… Read More